Tucci Jonathan, Alhushki Waseem, Chen Ting, Sheng Xia, Kim Yong-Mi, Mittelman Steven D
1Diabetes and Obesity Program, Center for Endocrinology, Diabetes and Metabolism, Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, CA USA.
2Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, CA USA.
Cancer Metab. 2018 Nov 1;6:15. doi: 10.1186/s40170-018-0189-0. eCollection 2018.
It is becoming increasingly recognized that weight and nutritional status can impact cancer survival. We have previously shown that obese mice with syngeneic acute lymphoblastic leukemia (ALL) have poorer response to chemotherapy treatment than control mice. We therefore investigated whether dietary intervention could improve outcome from the most common pediatric cancer, ALL.
Diet-induced obese (DIO) mice raised on a 60% calories from fat diet and control mice were implanted with syngeneic ALL cells. Some DIO mice were switched to the low-fat control diet. Survival from ALL was assessed without or with chemotherapy treatment starting at the time of the diet switch. Cells from DIO mice before and after diet switch were assessed by FACS for BrdU incorporation and phosphorylation status of AKT, S6K, and EIF2a. Similar experiments were done with human ALL xenografts. Mouse and human ALL cells were cultured in media with 10% or 5% fetal bovine serum, and sensitivity to chemotherapies assessed.
DIO mice had poorer survival (17%) after vincristine monotherapy than control mice on a 10% low fat diet (42%; = 12/group; = 0.09, log rank). However, switching obese mice to the low-fat diet prior to initiation of vincristine led to dramatically improved survival (92%, < 0.01 vs both other groups). In vitro, FBS restriction made murine and human ALL cells more sensitive to vincristine. Interestingly, while serum restriction enhanced ALL sensitivity to dexamethasone and l-asparaginase, dietary switch did not improve survival of DIO mice treated with either drug in monotherapy. Thus, it appears that dietary intervention has a unique effect to improve ALL cell sensitivity to vincristine in vivo.
We report herein that a dietary intervention can improve ALL outcome in a preclinical model. Further work is needed to identify the mechanisms of this effect and investigate potential impact on human leukemia in patients.
体重和营养状况会影响癌症生存率这一观点正日益得到认可。我们之前已经表明,患有同基因急性淋巴细胞白血病(ALL)的肥胖小鼠对化疗治疗的反应比对照小鼠差。因此,我们研究了饮食干预是否能改善最常见的儿童癌症——ALL的治疗结果。
将以含60%脂肪热量的饮食饲养的饮食诱导肥胖(DIO)小鼠和对照小鼠植入同基因ALL细胞。一些DIO小鼠改为低脂对照饮食。从饮食转换时开始,评估未经化疗或接受化疗的ALL小鼠的生存率。通过流式细胞术(FACS)评估饮食转换前后DIO小鼠细胞的BrdU掺入情况以及AKT、S6K和EIF2a的磷酸化状态。对人ALL异种移植瘤进行了类似实验。将小鼠和人ALL细胞在含10%或5%胎牛血清的培养基中培养,并评估其对化疗药物的敏感性。
长春新碱单药治疗后,DIO小鼠的生存率(17%)低于低脂饮食的对照小鼠(42%;每组n = 12;P = 0.09,对数秩检验)。然而,在开始长春新碱治疗前将肥胖小鼠改为低脂饮食可显著提高生存率(92%,与其他两组相比P < 0.01)。在体外,限制胎牛血清使小鼠和人ALL细胞对长春新碱更敏感。有趣的是,虽然血清限制增强了ALL对地塞米松和左旋门冬酰胺酶的敏感性,但饮食转换并未改善接受这两种药物单药治疗的DIO小鼠的生存率。因此,饮食干预似乎对提高ALL细胞在体内对长春新碱的敏感性具有独特作用。
我们在此报告,饮食干预可改善临床前模型中ALL的治疗结果。需要进一步开展工作以确定这种作用的机制,并研究其对人类白血病患者的潜在影响。